3Chopt Investment Partners LLC Makes New $409,000 Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

3Chopt Investment Partners LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 821 shares of the medical research company's stock, valued at approximately $409,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $25,000. Pillar Financial Advisors LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $30,000. Noble Wealth Management PBC purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $35,000. Finally, Cassady Schiller Wealth Management LLC raised its stake in Thermo Fisher Scientific by 89.2% in the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after buying an additional 33 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Up 3.9%

TMO traded up $15.89 on Tuesday, reaching $421.35. 2,603,007 shares of the company's stock were exchanged, compared to its average volume of 1,964,289. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company's 50 day moving average is $409.41 and its 200-day moving average is $482.09. The company has a market cap of $159.06 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 2.16 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the company earned $5.11 earnings per share. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.41%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. Stifel Nicolaus lowered their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Evercore ISI decreased their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Argus dropped their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Citigroup decreased their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, Royal Bank Of Canada lowered their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $604.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.